Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Buy” from Analysts


Share on StockTwits

Affimed (NASDAQ:AFMD) has been given a consensus rating of “Buy” by the six brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $13.80.

AFMD has been the topic of a number of analyst reports. SVB Leerink lifted their target price on shares of Affimed from $9.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 17th. Wells Fargo & Company lifted their price target on shares of Affimed from $10.00 to $15.00 and gave the company an “overweight” rating in a research report on Tuesday, March 30th. BMO Capital Markets lifted their price target on shares of Affimed from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Credit Suisse Group started coverage on shares of Affimed in a research report on Tuesday, March 30th. They set an “outperform” rating and a $15.00 price target for the company.

NASDAQ:AFMD opened at $10.00 on Monday. The company’s 50-day moving average price is $6.92 and its 200-day moving average price is $5.57. The company has a market cap of $883.26 million, a P/E ratio of -16.51 and a beta of 2.81. Affimed has a twelve month low of $1.88 and a twelve month high of $10.70.

A number of hedge funds and other institutional investors have recently bought and sold shares of AFMD. Captrust Financial Advisors acquired a new position in Affimed during the 4th quarter worth approximately $29,000. ExodusPoint Capital Management LP acquired a new position in Affimed during the 3rd quarter worth approximately $62,000. Fox Run Management L.L.C. acquired a new position in Affimed during the 4th quarter worth approximately $73,000. Lindbrook Capital LLC grew its holdings in Affimed by 160.0% during the 4th quarter. Lindbrook Capital LLC now owns 13,000 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in Affimed during the 4th quarter worth approximately $76,000. Institutional investors own 52.33% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Story: Futures Contract

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.